PT - JOURNAL ARTICLE AU - Antonio Leidi AU - Flora Koegler AU - Roxane Dumont AU - Richard Dubos AU - María-Eugenia Zaballa AU - Giovanni Piumatti AU - Matteo Coen AU - Amandine Berner AU - Pauline Darbellay Farhoumand AU - Pauline Vetter AU - Nicolas Vuilleumier AU - Laurent Kaiser AU - Delphine Courvoisier AU - Andrew S Azman AU - Idris Guessous AU - Silvia Stringhini AU - SEROCoV-POP study group TI - Risk of reinfection after seroconversion to SARS-CoV-2: A population-based propensity-score matched cohort study AID - 10.1101/2021.03.19.21253889 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.19.21253889 4099 - http://medrxiv.org/content/early/2021/03/20/2021.03.19.21253889.short 4100 - http://medrxiv.org/content/early/2021/03/20/2021.03.19.21253889.full AB - Importance Serological assays detecting specific IgG antibodies generated against the Spike protein following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection are being widely deployed in research studies and clinical practice. However, the duration and the effectiveness of the protection conferred by the immune response against future infection remains to be assessed in a large population.Objective To estimate the incidence of newly acquired SARS-CoV-2 infections in seropositive individuals from a population-based sample as compared to seronegative controls.Design Retrospective longitudinal propensity-score matched cohort study.Setting A seroprevalence survey including a population-based representative sample of the population from the canton of Geneva (Switzerland) was conducted between April and June 2020, immediately after the first pandemic wave. Each individual included in the seroprevalence survey was linked to a state centralized registry compiling virologically confirmed SARS-CoV-2 infections since the beginning of the pandemic.Participants Participants aged twelve years old and over, who developed anti-spike IgG antibodies were matched one-to-two to seronegative controls, using a propensity-score including age, gender, immunodeficiency, body mass index, smoking status and education level.Exposure SARS-CoV-2 seropositivity.Main outcomes and measures Our primary outcome was virologically confirmed SARS-CoV-2 infections which occurred from serological status assessment in April-June 2020 to the end of the second pandemic wave (January 2021). Additionally, incidence of infections, rate of testing and proportion of positive tests were analysed.Results Among 8344 serosurvey participants, 498 seropositive individuals were selected and matched with 996 seronegative controls. After a mean follow-up of 35.6 (Standard Deviation, SD: 3.2) weeks, 7 out of 498 (1.4%) seropositive subjects had a positive SARS-CoV-2 test, of which 5 (1.0%) were considered as reinfections. By contrast, infection rate was significantly higher in seronegative individuals (15.5%, 154/996) during a similar mean follow-up of 34.7 (SD 3.2) weeks, corresponding to a 94% (95%CI 86% to 98%, P<0.001) reduction in the hazard of having a positive SARS-CoV-2 test for seropositive subjects.Conclusions and relevance Seroconversion after SARS-CoV-2 infection confers protection to successive viral contamination lasting at least 8 months. These findings could help global health authorities establishing priority for vaccine allocation.Question Do SARS-CoV-2 antibodies confer protection against future infection?Findings In this retrospective matched cohort study nested in a representative sample of the general population of Geneva, Switzerland, we observed a 94% reduction in the hazard of being infected among participants with antibodies against SARS-CoV-2, when compared to seronegative controls, >8 months after initial serology assessment.Meaning Seroconversion to SARS-CoV-2 is associated with a large and sustained protection against reinfection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNo study registration due to retrospective designFunding StatementThis study was funded by the Swiss Federal Office of Public Health, the General Directorate of Health of the Department of Safety, Employment and Health of the canton of Geneva, the Private Foundation of the Geneva University Hospitals, the Swiss School of Public Health (Corona Immunitas Research Program), the Charity Foundation of Groupe Pictet, the Fondation Ancrage, the Fondation des Grangettes and the Geneva Center for Emerging Viral Diseases. The founders have no role in the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Regional Research Ethics Committee of Geneva (CCER) Rue Adrien-Lachenal 8 1207 GenevaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur data are accessible to researchers upon reasonable request for data sharing to the corresponding author.